Payment overview · 2025
General Payments
$669.56
23 reported records · 7 companies
Healthcare provider profile · identity verified
Antonio M Phillips, MD
Allopathic & Osteopathic Physicians|Family Medicine · COLUMBUS, OH · NPI 1679684344
Verified facts
What the public records show
CMS Open Payments records show Antonio M Phillips, MD received $669.56 in general payments during 2025 across 23 reported records.
Lilly USA, LLC accounted for 24.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $162.34 | 24.2% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $135.80 | 20.3% | 7 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $134.64 | 20.1% | 6 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $121.93 | 18.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $71.15 | 10.6% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $25.20 | 3.8% | 1 | 2025 |
| Pulmonx Corporation | Unresolved — no canonical attribution shown | $18.50 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $669.56 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $162.34 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $135.80 | 7 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $134.64 | 6 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $121.93 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $71.15 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $46.77 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $25.20 | 1 | 2025 |
Source payment records
|
|||||
| CHARTIS CATHETER Normalized: chartis catheter |
Device | Pulmonx Corporation | $18.50 | 1 | 2025 |
Source payment records
|
|||||
| PULMONX CHARTIS TABLET CONSOLE Normalized: pulmonx chartis tablet console |
Device | Pulmonx Corporation | $18.50 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR DELIVERY CATHETER Normalized: zephyr delivery catheter |
Device | Pulmonx Corporation | $18.50 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR ENDOBRONCHIAL VALVE Normalized: zephyr endobronchial valve |
Device | Pulmonx Corporation | $18.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
145 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
91 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 402 | 90 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 320 | 77 |
| Amlodipine Besylate | Amlodipine Besylate | 296 | 69 |
| Losartan Potassium | Losartan Potassium | 207 | 44 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 206 | 44 |
| Gabapentin | Gabapentin | 199 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 191 | 42 |
| Lisinopril | Lisinopril | 190 | 42 |
| Omeprazole | Omeprazole | 190 | 44 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 182 | 49 |
| Metformin Hcl Er | Metformin Hcl | 177 | 38 |
| Furosemide | Furosemide | 155 | 42 |
| Jardiance | Empagliflozin | 145 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 141 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 136 | 31 |
| Ibuprofen | Ibuprofen | 130 | 36 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 125 | 28 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 124 | 25 |
| Trazodone Hcl | Trazodone Hcl | 123 | 28 |
| Levothyroxine Sodium | Levothyroxine Sodium | 119 | 23 |
| Potassium Chloride | Potassium Chloride | 119 | 37 |
| Simvastatin | Simvastatin | 105 | 22 |
| Sertraline Hcl | Sertraline Hcl | 104 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 94 | 30 |
| Fluconazole | Fluconazole | 91 | 26 |
| Trulicity | Dulaglutide | 91 | 17 |
| Famotidine | Famotidine | 89 | 27 |
| Pioglitazone Hcl | Pioglitazone Hcl | 83 | 18 |
| Carvedilol | Carvedilol | 82 | 19 |
| Clonidine Hcl | Clonidine Hcl | 76 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 68 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 68 | suppressed |
| Metformin Hcl | Metformin Hcl | 65 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 20 |
| Azithromycin | Azithromycin | 59 | 48 |
| Farxiga | Dapagliflozin Propanediol | 59 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 59 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 57 | 14 |
| Naproxen | Naproxen | 54 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 54 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 53 | 14 |
| Roflumilast | Roflumilast | 52 | 16 |
| Topiramate | Topiramate | 52 | 12 |
| Buspirone Hcl | Buspirone Hcl | 51 | suppressed |
| Ozempic | Semaglutide | 49 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 47 | suppressed |
| Prednisone | Prednisone | 46 | 31 |
| Alendronate Sodium | Alendronate Sodium | 44 | 14 |
| Meloxicam | Meloxicam | 42 | 11 |
| Eliquis | Apixaban | 38 | suppressed |
| Januvia | Sitagliptin Phosphate | 38 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 38 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 37 | suppressed |
| Risperidone | Risperidone | 37 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 36 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 36 | suppressed |
| Linzess | Linaclotide | 36 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 36 | suppressed |
| Ondansetron Odt | Ondansetron | 36 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 33 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | suppressed |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Klor-Con M20 | Potassium Chloride | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 26 | 22 |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 24 | 14 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 24 | suppressed |
| Methotrexate | Methotrexate Sodium | 23 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 22 | suppressed |
| Ketoconazole | Ketoconazole | 22 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 21 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 18 | suppressed |
| Allopurinol | Allopurinol | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 12 |
| Single Use Swab | Alcohol Antiseptic Pads | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | 11 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 14 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Olopatadine Hcl | Olopatadine Hcl | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $669.56 · 23 records | Lilly USA, LLC | CHARTIS CATHETER, Cologuard Collection Kit, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, MOUNJARO, PULMONX CHARTIS TABLET CONSOLE, Veozah, Wegovy, ZEPBOUND, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error